Clinical Trial Update: Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating vedolizumab with post-transplant cyclophosphamide and tacrolimus to prevent graft-versus-host disease in patients undergoing allogeneic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Graft-versus-host Disease
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia
• Myeloproliferative Neoplasm

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Tacrolimus (Tacrolimus)
• Vedolizumab (vedolizumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING